Legend Biotech (LEGN) Reports 70% Disease Control Rate in Phase 1 LB2102 Cancer Trial

Legend Biotech Corp. (NASDAQ: LEGN) on June 2, 2026, reported positive Phase 1 data for its investigational drug LB2102, showing a 70% disease control rate in patients with advanced solid tumors. The trial evaluated the DLL3-targeted CAR-T therapy in patients who had exhausted standard treatments. The company said the safety profile was manageable, with no unexpected toxicities. The results mark a pipeline expansion for Legend, which gained FDA approval for its multiple myeloma therapy Carvykti in partnership with Johnson & Johnson. LB2102 is being studied for small cell lung cancer and other DLL3-expressing tumors. Legend plans to advance the therapy into later-stage trials. Shares of Legend Biotech rose in early trading following the announcement.